Vaxxinity Inc
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial … Read more
Vaxxinity Inc (VAXX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2024: -0.883x
Based on the latest financial reports, Vaxxinity Inc (VAXX) has a cash flow conversion efficiency ratio of -0.883x as of March 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.85 Million) by net assets ($13.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vaxxinity Inc - Cash Flow Conversion Efficiency Trend (2019–2023)
This chart illustrates how Vaxxinity Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Vaxxinity Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vaxxinity Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ESGL Holdings Limited Warrants
NASDAQ:ESGLW
|
0.093x |
|
Knusford Bhd
KLSE:5035
|
0.011x |
|
ELIA SYSTEM OP. (E4S.SG)
STU:E4S
|
N/A |
|
Tomer Energy Royalties 2012 Ltd
TA:TOEN
|
0.020x |
|
EXXON MOBIL - Dusseldorf Stock Exchang
DU:XONA
|
0.064x |
|
WILDCAT PRETR.LS -000028
F:8Y6
|
N/A |
|
Ucommune International Ltd
NASDAQ:UK
|
-0.017x |
|
Valora Effekten Handel AG
F:VEH
|
N/A |
Annual Cash Flow Conversion Efficiency for Vaxxinity Inc (2019–2023)
The table below shows the annual cash flow conversion efficiency of Vaxxinity Inc from 2019 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $13.41 Million | $-57.24 Million | -4.269x | -374.56% |
| 2022-12-31 | $62.18 Million | $-55.93 Million | -0.899x | -42.85% |
| 2021-12-31 | $128.62 Million | $-80.99 Million | -0.630x | -262.25% |
| 2020-12-31 | $-87.38 Million | $-33.91 Million | 0.388x | +53.50% |
| 2019-12-31 | $-48.51 Million | $-12.27 Million | 0.253x | -- |